iRadimed Corporation (IRMD) To Go Ex-Dividend on February 23rd

iRadimed Corporation (NASDAQ:IRMD) declared a quarterly dividend on Tuesday, February 10th. Shareholders of record on Monday, February 23rd will be given a dividend of 0.20 per share by the medical equipment provider on Friday, March 6th. This represents a c) dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Monday, February 23rd. This is a 17.6% increase from iRadimed’s previous quarterly dividend of $0.17.

iRadimed has a payout ratio of 40.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect iRadimed to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 40.0%.

iRadimed Stock Down 2.0%

NASDAQ:IRMD opened at $103.08 on Thursday. iRadimed has a twelve month low of $47.48 and a twelve month high of $107.90. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 58.90 and a beta of 1.11. The stock’s 50 day moving average price is $98.28 and its two-hundred day moving average price is $83.57.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. The business had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, analysts anticipate that iRadimed will post 1.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IRMD. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Lake Street Capital reiterated a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.